Partners with South Korea’s Kai Health, launches AI-powered Vita Embryo across Nova’s 120 clinics in 65 cities
Nova IVF Fertility has announced the integration of Artificial Intelligence (AI) into its IVF labs to bring in greater precision and trust to embryo selection, an extremely crucial element of fertility treatment. The fertility chain will implement Vita Embryo, an AI-based embryo assessment, across its 120 clinics in 65 cities. This is implemented through Nova IVF’s partnership with South Korea’s AI technology firm Kai Health. This technology aims to improve pregnancy rates, reduce the time of a patient’s IVF cycle, and bring in better transparency in the fertility treatment.
One of the most critical moments in IVF treatment is the selection of the right embryo. Within the IVF Lab, Clinical Embryologists apply years of expertise, grading each embryo on its capacity to develop into a pregnancy. AI aids in spotting minute details regarding embryo health that may be too subtle for a human eye.
Nova IVF Fertility is operated by Asia Healthcare Holdings, and performs over 20,000 IVF cycles annually across more than 120 clinics nationwide. With the initial implementation of Vita Embryo already underway in 20 locations, it is expected to be adopted throughout the network by the end of the year.
Kai Health attained medical device certification for Vita Embryo in Europe, Singapore, Korea, and India. Clinical tests indicate that AI-powered Vita Embryo can double the accuracy of embryo selection compared to human evaluation, providing couples with a better chance of attaining a successful outcome.
Key Highlights:
- AI and Big Data play a big role in providing highly accurate analysis
- A survey conducted by Artificial Intelligence’s efficacy by Kai Health also indicated how the precision of selecting embryos increased by 12 per cent
- This can save time for patients undergoing IVF treatment, as embryo selection is faster